trending Market Intelligence /marketintelligence/en/news-insights/trending/cnnolr07orhow1pz8r5new2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Profound Medical names 2 directors

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Profound Medical names 2 directors

Profound Medical Corp. shareholders elected two new directors at the company's June 14 annual meeting.

Arthur Rosenthal and Brian Ellacott will serve as independent directors of Ontario-based Profound Medical.

Rosenthal is CEO of gEyeCue Ltd., a development stage medical device company. His previous roles include senior vice president and chief scientific officer of Boston Scientific Corp. and vice president of research and development at C. R. Bard Inc., now a unit of Becton Dickinson and Co.

Ellacott is CEO of Belmont Instrument Corp., a medical device company focused on fluid warming and infusion systems. Previously, he was president and CEO of Laborie Medical Technologies.

Medical device company Profound Medical develops and sells technologies to ablate the prostate gland in patients with prostate cancer.